Uterine Fibroids Treatment Market 2024 - By Growth Analysis, Opportunities, Business Insights, Key Trends And Forecast By 2033

 

The Uterine Fibroids Treatment Global Market Report 2024 by The Business Research Company provides market overview across 60+ geographies in the seven regions - Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa, encompassing 27 major global industries. The report presents a comprehensive analysis over a ten-year historic period (2010-2021) and extends its insights into a ten-year forecast period (2023-2033).

 

Learn More On The Uterine Fibroids Treatment Market:

https://www.thebusinessresearchcompany.com/report/uterine-fibroids-treatment-global-market-report

 

According to The Business Research Company’s Uterine Fibroids Treatment Global Market Report 2024, The uterine fibroids treatment market size has grown rapidly in recent years. It will grow from $3.67 billion in 2023 to $4.04 billion in 2024 at a compound annual growth rate (CAGR) of 10.0%. The  growth in the historic period can be attributed to increased incidence of uterine fibroids, advancements in diagnostic techniques, rising awareness and education, impact on quality of life, evolution of minimally invasive procedures..

 

The uterine fibroids treatment market size is expected to see strong growth in the next few years. It will grow to $5.77 billion in 2028 at a compound annual growth rate (CAGR) of 9.3%. The growth in the forecast period can be attributed to advancements in non-invasive treatment, increasing emphasis on fertility preservation, rise in minimally invasive techniques, personalized medicine approaches, collaborative research and development.. Major trends in the forecast period include rising focus on fertility-preserving treatments, integration of imaging technologies in treatment planning, increasing awareness and education initiatives, customized treatment plans based on patient profiles, exploration of novel therapeutic targets..

 

The high prevalence of uterine fibroids among women is expected to propel the growth of the uterine fibroids treatment market going forward. Uterine fibroids refer to non-cancerous growths that develop in the uterus and can cause symptoms such as heavy menstrual bleeding, pelvic pain, and pressure on the bladder or bowel. Uterine fibroids treatment treats fibroids by blocking the production of estrogen and progesterone and stopping menstruation and improving anemia. For instance, in November 2022, according to a report published by the National Centre for Biotechnology Information, a US-based organization, and branch of the National Institutes of Health, the approximate incidence of uterine fibroids occurs between 40 and 60% among women under the age of 35 and between 70- 80% among women over the age of 50. Therefore, the high prevalence of uterine fibroids among women worldwide is driving the growth of the uterine fibroids treatment market.

 

Get A Free Sample Of The Report (Includes Graphs And Tables):

https://www.thebusinessresearchcompany.com/sample.aspx?id=10766&type=smp

 

The uterine fibroids treatment market covered in this report is segmented –

1) By Type: Subserosal Fibroids, Intramural Fibroids, Submucosal Fibroids, Pedunculated Fibroids

2) By Treatment Type: Hormone Therapy, Androgens, Gonadotropin-Releasing Hormone Antagonists, Uterine Artery Embolization, Myomectomy, Hysterectomy

3) By End-Users: Hospitals, Ambulatory Surgical Centers, Other End users

 

Top Major Players

Gynesonics Inc.

Medtronic PLC

Boston Scientific Corporation

Karl Storz GmbH

Pfizer Inc.

 

Product innovations are a key trend gaining popularity in the uterine fibroid treatment market. Companies operating in the uterine fibroid treatment market are adopting innovative products to sustain their position in the market. For instance, in May 2021, Myovant Sciences, a Switzerland-based healthcare company, and Pfizer, a US-based multinational pharmaceutical and biotechnology corporation, received FDA approval for MYFEMBREE (relugolix 40 mg, estradiol 1 mg, and norethindrone acetate 0.5 mg). This is the first once-daily treatment with a maximum 24-month treatment duration for the control of severe monthly bleeding brought on by uterine fibroids in premenopausal women.

 

The uterine fibroids treatment market report table of contents includes:

1. Executive Summary

2. Uterine Fibroids Treatment Market Characteristics

3. Uterine Fibroids Treatment Market Trends And Strategies

4. Uterine Fibroids Treatment Market - Macro Economic Scenario

5. Global Uterine Fibroids Treatment Market Size and Growth

.........................

31. Global Uterine Fibroids Treatment Market Competitive Benchmarking

32. Global Uterine Fibroids Treatment Market Competitive Dashboard

33. Key Mergers And Acquisitions In The Uterine Fibroids Treatment Market

34. Uterine Fibroids Treatment Market Future Outlook and Potential Analysis

35. Appendix

 

Contact Us:

The Business Research Company

Europe: +44 207 1930 708

Asia: +91 88972 63534

Americas: +1 315 623 0293

Email: info@tbrc.info

 

Follow Us On:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

Twitter: https://twitter.com/tbrc_info 

Facebook: https://www.facebook.com/TheBusinessResearchCompany

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Blog: https://blog.tbrc.info/

Healthcare Blog: https://healthcareresearchreports.com/

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model